Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SRDX's Cash to Debt is ranked higher than
96% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. SRDX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SRDX' s Cash to Debt Range Over the Past 10 Years
Min: No Debt  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.85
SRDX's Equity to Asset is ranked higher than
84% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. SRDX: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
SRDX' s Equity to Asset Range Over the Past 10 Years
Min: 0.74  Med: 0.92 Max: 0.95
Current: 0.85
0.74
0.95
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
90% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. SRDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SRDX' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 8
Z-Score: 26.01
M-Score: -2.38
WACC vs ROIC
7.00%
26.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 28.01
SRDX's Operating margin (%) is ranked higher than
95% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. SRDX: 28.01 )
Ranked among companies with meaningful Operating margin (%) only.
SRDX' s Operating margin (%) Range Over the Past 10 Years
Min: -20.11  Med: 31.16 Max: 51.75
Current: 28.01
-20.11
51.75
Net-margin (%) 16.88
SRDX's Net-margin (%) is ranked higher than
91% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. SRDX: 16.88 )
Ranked among companies with meaningful Net-margin (%) only.
SRDX' s Net-margin (%) Range Over the Past 10 Years
Min: -35.08  Med: 19.50 Max: 30.9
Current: 16.88
-35.08
30.9
ROE (%) 12.22
SRDX's ROE (%) is ranked higher than
81% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. SRDX: 12.22 )
Ranked among companies with meaningful ROE (%) only.
SRDX' s ROE (%) Range Over the Past 10 Years
Min: -12.91  Med: 11.66 Max: 23.9
Current: 12.22
-12.91
23.9
ROA (%) 11.19
SRDX's ROA (%) is ranked higher than
90% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. SRDX: 11.19 )
Ranked among companies with meaningful ROA (%) only.
SRDX' s ROA (%) Range Over the Past 10 Years
Min: -11.85  Med: 9.89 Max: 19.94
Current: 11.19
-11.85
19.94
ROC (Joel Greenblatt) (%) 94.74
SRDX's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. SRDX: 94.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SRDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -18.72  Med: 89.94 Max: 154.38
Current: 94.74
-18.72
154.38
Revenue Growth (3Y)(%) 16.10
SRDX's Revenue Growth (3Y)(%) is ranked higher than
81% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. SRDX: 16.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SRDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.6  Med: 15.50 Max: 57.8
Current: 16.1
-24.6
57.8
EBITDA Growth (3Y)(%) 14.10
SRDX's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. SRDX: 14.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SRDX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.6  Med: 14.10 Max: 92.2
Current: 14.1
-32.6
92.2
EPS Growth (3Y)(%) 15.80
SRDX's EPS Growth (3Y)(%) is ranked higher than
77% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. SRDX: 15.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SRDX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.4  Med: 11.80 Max: 47.9
Current: 15.8
-35.4
47.9
» SRDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SRDX Guru Trades in Q1 2015

Mario Gabelli 117,948 sh (-2.03%)
Chuck Royce 700,800 sh (-2.45%)
Jim Simons 564,838 sh (-3.07%)
Mairs and Power 39,440 sh (-3.31%)
» More
Q2 2015

SRDX Guru Trades in Q2 2015

Jim Simons 606,135 sh (+7.31%)
Chuck Royce 593,000 sh (-15.38%)
Mairs and Power 31,690 sh (-19.65%)
Mario Gabelli 92,148 sh (-21.87%)
» More
Q3 2015

SRDX Guru Trades in Q3 2015

Jim Simons 635,038 sh (+4.77%)
Mario Gabelli 90,548 sh (-1.74%)
Chuck Royce 574,200 sh (-3.17%)
Mairs and Power 30,590 sh (-3.47%)
» More
Q4 2015

SRDX Guru Trades in Q4 2015

Jim Simons 754,938 sh (+18.88%)
Mario Gabelli 90,548 sh (unchged)
Chuck Royce 523,200 sh (-8.88%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.39
SRDX's P/E(ttm) is ranked higher than
76% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.30 vs. SRDX: 20.39 )
Ranked among companies with meaningful P/E(ttm) only.
SRDX' s P/E(ttm) Range Over the Past 10 Years
Min: 8.52  Med: 28.51 Max: 584.75
Current: 20.39
8.52
584.75
Forward P/E 23.58
SRDX's Forward P/E is ranked lower than
75% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.02 vs. SRDX: 23.58 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.39
SRDX's PE(NRI) is ranked higher than
76% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. SRDX: 20.39 )
Ranked among companies with meaningful PE(NRI) only.
SRDX' s PE(NRI) Range Over the Past 10 Years
Min: 8.48  Med: 27.81 Max: 519.78
Current: 20.39
8.48
519.78
P/B 2.54
SRDX's P/B is ranked lower than
52% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. SRDX: 2.54 )
Ranked among companies with meaningful P/B only.
SRDX' s P/B Range Over the Past 10 Years
Min: 0.98  Med: 3.29 Max: 7.77
Current: 2.54
0.98
7.77
P/S 3.81
SRDX's P/S is ranked lower than
73% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. SRDX: 3.81 )
Ranked among companies with meaningful P/S only.
SRDX' s P/S Range Over the Past 10 Years
Min: 2.16  Med: 5.72 Max: 13.76
Current: 3.81
2.16
13.76
PFCF 18.70
SRDX's PFCF is ranked higher than
75% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.68 vs. SRDX: 18.70 )
Ranked among companies with meaningful PFCF only.
SRDX' s PFCF Range Over the Past 10 Years
Min: 7.26  Med: 21.55 Max: 511.5
Current: 18.7
7.26
511.5
POCF 16.41
SRDX's POCF is ranked higher than
59% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.98 vs. SRDX: 16.41 )
Ranked among companies with meaningful POCF only.
SRDX' s POCF Range Over the Past 10 Years
Min: 5.98  Med: 17.23 Max: 30.1
Current: 16.41
5.98
30.1
EV-to-EBIT 10.54
SRDX's EV-to-EBIT is ranked higher than
81% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.25 vs. SRDX: 10.54 )
Ranked among companies with meaningful EV-to-EBIT only.
SRDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.4  Med: 15.80 Max: 248.4
Current: 10.54
-47.4
248.4
EV-to-EBITDA 9.18
SRDX's EV-to-EBITDA is ranked higher than
72% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.20 vs. SRDX: 9.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -167.5  Med: 13.60 Max: 110.4
Current: 9.18
-167.5
110.4
Shiller P/E 31.86
SRDX's Shiller P/E is ranked higher than
63% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.56 vs. SRDX: 31.86 )
Ranked among companies with meaningful Shiller P/E only.
SRDX' s Shiller P/E Range Over the Past 10 Years
Min: 17.08  Med: 41.50 Max: 128.98
Current: 31.86
17.08
128.98
Current Ratio 14.42
SRDX's Current Ratio is ranked higher than
95% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. SRDX: 14.42 )
Ranked among companies with meaningful Current Ratio only.
SRDX' s Current Ratio Range Over the Past 10 Years
Min: 1.77  Med: 4.92 Max: 14.42
Current: 14.42
1.77
14.42
Quick Ratio 13.79
SRDX's Quick Ratio is ranked higher than
94% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. SRDX: 13.79 )
Ranked among companies with meaningful Quick Ratio only.
SRDX' s Quick Ratio Range Over the Past 10 Years
Min: 1.69  Med: 4.58 Max: 13.79
Current: 13.79
1.69
13.79
Days Inventory 126.73
SRDX's Days Inventory is ranked lower than
65% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. SRDX: 126.73 )
Ranked among companies with meaningful Days Inventory only.
SRDX' s Days Inventory Range Over the Past 10 Years
Min: 33.96  Med: 123.11 Max: 168.39
Current: 126.73
33.96
168.39
Days Sales Outstanding 31.38
SRDX's Days Sales Outstanding is ranked higher than
90% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. SRDX: 31.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.19  Med: 39.87 Max: 80.51
Current: 31.38
30.19
80.51
Days Payable 42.27
SRDX's Days Payable is ranked lower than
75% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. SRDX: 42.27 )
Ranked among companies with meaningful Days Payable only.
SRDX' s Days Payable Range Over the Past 10 Years
Min: 33.07  Med: 71.36 Max: 166.09
Current: 42.27
33.07
166.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.31
SRDX's Price/Net Cash is ranked lower than
53% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.81 vs. SRDX: 9.31 )
Ranked among companies with meaningful Price/Net Cash only.
SRDX' s Price/Net Cash Range Over the Past 10 Years
Min: 5.81  Med: 31.39 Max: 107.95
Current: 9.31
5.81
107.95
Price/Net Current Asset Value 6.61
SRDX's Price/Net Current Asset Value is ranked higher than
51% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. SRDX: 6.61 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SRDX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.27  Med: 18.09 Max: 119.54
Current: 6.61
4.27
119.54
Price/Tangible Book 4.21
SRDX's Price/Tangible Book is ranked higher than
52% of the 218 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. SRDX: 4.21 )
Ranked among companies with meaningful Price/Tangible Book only.
SRDX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.26  Med: 4.22 Max: 12.03
Current: 4.21
1.26
12.03
Price/Projected FCF 1.07
SRDX's Price/Projected FCF is ranked higher than
78% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.89 vs. SRDX: 1.07 )
Ranked among companies with meaningful Price/Projected FCF only.
SRDX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.42 Max: 4.3
Current: 1.07
0.52
4.3
Price/Median PS Value 0.70
SRDX's Price/Median PS Value is ranked higher than
72% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. SRDX: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
SRDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 1.34 Max: 5.46
Current: 0.7
0.52
5.46
Price/Peter Lynch Fair Value 4.19
SRDX's Price/Peter Lynch Fair Value is ranked lower than
91% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. SRDX: 4.19 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SRDX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.55  Med: 1.91 Max: 17.26
Current: 4.19
0.55
17.26
Price/Graham Number 2.04
SRDX's Price/Graham Number is ranked higher than
58% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. SRDX: 2.04 )
Ranked among companies with meaningful Price/Graham Number only.
SRDX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.9  Med: 2.72 Max: 10.43
Current: 2.04
0.9
10.43
Earnings Yield (Greenblatt) (%) 9.50
SRDX's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. SRDX: 9.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SRDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 5.90 Max: 22
Current: 9.5
0.4
22
Forward Rate of Return (Yacktman) (%) 28.43
SRDX's Forward Rate of Return (Yacktman) (%) is ranked higher than
88% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. SRDX: 28.43 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SRDX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.1  Med: 3.50 Max: 36.4
Current: 28.43
1.1
36.4

More Statistics

Revenue(Mil) $64
EPS $ 0.83
Beta0.70
Short Percentage of Float9.82%
52-Week Range $17.62 - 27.68
Shares Outstanding(Mil)13.00

Analyst Estimate

Sep16 Sep17 Sep18
Revenue(Mil) 64 66 71
EPS($) 0.47 0.79 1.01
EPS without NRI($) 0.47 0.79 1.01

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
SurModics Inc was organized as a Minnesota corporation in June 1979. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. Its business units are organized and managed in two reportable segments, Medical Device and In Vitro Diagnostics. The core offerings in its Medical Device business unit include surface modification coating technologies that impart lubricity, prohealing or biocompatibility characteristics, or drug delivery capabilities. It manufactures or sells components for in vitro diagnostic immunoassay and molecular tests and it manufactures and sells surface coatings to the diagnostic, biomedical research, and life science markets. The In Vitro Diagnostics products include Protein Stabilizers, Substrates, Recombinant Human Antigens, and Surface Coatings for Molecular Diagnostic Applications.
» More Articles for SRDX

Headlines

Articles On GuruFocus.com
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 11 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
SURMODICS INC Financials Feb 11 2016
SURMODICS INC Files SEC form 10-Q, Quarterly Report Feb 05 2016
SURMODICS INC Files SEC form 8-K/A, Financial Statements and Exhibits Feb 03 2016
SurModics, Inc. Earnings Analysis: Q1, 2016 By the Numbers Feb 02 2016
SurModics' (SRDX) Q1 Earnings & Revenues Beat Estimates Jan 29 2016
SurModics Inc Earnings Call scheduled for 8:30 am ET today Jan 28 2016
SurModics Reports First Quarter Fiscal 2016 Results Jan 28 2016
SurModics posts 1Q profit Jan 28 2016
SurModics posts 1Q profit Jan 28 2016
SURMODICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 28 2016
SurModics Reports First Quarter Fiscal 2016 Results Jan 28 2016
Q1 2016 SurModics Inc Earnings Release - Before Market Open Jan 28 2016
SurModics to Webcast First Quarter 2016 Earnings Conference Call on January 28 Jan 21 2016
SurModics to Webcast First Quarter 2016 Earnings Conference Call on January 28 Jan 21 2016
SURMODICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Jan 13 2016
SurModics Buys NorMedix for $14M, Adjusts 2016 Outlook Jan 12 2016
SurModics increases exec pay; CEO Gary Maharaj got $1.48M in 2015 Jan 12 2016
SurModics Acquires NorMedix, a Design and Development Company Focused on Minimally Invasive Catheter... Jan 11 2016
SurModics Acquires NorMedix, a Design and Development Company Focused on Minimally Invasive Catheter... Jan 11 2016
SURMODICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK